WHO ICTRP trial
Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain…
PER-047-05 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-047-05 |
|---|---|
| Public title | Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subject |
| Scientific title | A multicentre, randomized, double-blind, placebo-controlled, phase IIb study to evaluate the efficacy and safety of Alvimopan administered in multiple dosing regimens for the treatment of opioid-induced intestinal dysfunction in patients with cancer pain |
| Primary sponsor | GLAXOSMITHKLINE PERU S.A., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | II |
| Countries | China;Korea South;Philippines;India;Pakistan;Spain;Finland;France;Poland;Portugal;United Kindgdom;Russian Federation;Australia;New Zealand;Czech Republic;Argentina;Canada;United States |
| Conditions | -K590 Constipation Constipation;K590;Constipation |
| Interventions | Group name:GROUP 1 Type of group;2 N° of participants:65 Intervention(s) description:Patients in this group will be treated with ALVIMOPAN placebo 2 times a day for 3 weeks Group name:GROUP 3 Type of group;1 N° of participants:65… |
| Registration date | Sep 28, 2005 |
| Target size | 8 |
| Secondary IDs | NA;2004-001814-14-GB |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: